Tropism Redirection News Today

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set

LEXINGTON, Mass., April 22, 2024 -- Voyager Therapeutics, Inc. , a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data...

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy -

Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells

Parkinsons disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which...

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) and Voyager Therapeutics Inc. (VYGR) said that they have collaborated to advance multiple gene therapies for the treatment of neurological

Voyager Therapeutics has promising technology. But the stock is very risky.

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties ...

Novartis gains target-specific access to next-generation AAV capsids that could be used for three diseases of the central nervous system, with options for two additional targets  

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access... | March 8, 2022